The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.
Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.
Mark Mascolini reports on a new study comparing statin indications in male veterans with HIV, HCV or both with three sets of cholesterol guidelines and examining why almost one-third of statin-eligible veterans were not getting the drugs.
The fixed-dose combination of sofosbuvir + velpatasvir (Epclusa) has been evaluated for possible and potential interactions with other drugs.
Starting antiretroviral therapy with a ritonavir (Norvir)-boosted protease inhibitor resulted in a higher incidence of chronic kidney disease (CKD), whether or not the regimen included tenofovir disoproxil fumarate (TDF, Viread), according to a recen...
Multiple dosing with doravirine does not change the plasma pharmacokinetics of a single dose of ethinyl estradiol or levonorgestrel to a clinically important extent, according to data shown at the 6th International Workshop on HIV and Women.
A team in Chicago recently reported an interaction between cobicistat and the transplant medicine tacrolimus (Advagraf, Prograf) in a person taking Stribild, and cautioned others to be mindful of the potential for interaction between these drugs.
Taking darunavir/cobicistat (Prezcobix) with a new HIV drug known as BMS-663068, which is currently being studied, was safe and did not cause any serious reactions in two studies.
Antiretroviral combinations including a protease inhibitor led to undetectable viral loads more often when people took their pills on time at least 95% of the time than when they took their pills less often.